Market News / Story
Okogen, Inc. Wins CDSCO OK to Start EMERALD Phase 1/2 Trial
·
Okogen received authorization from India’s CDSCO to advance EMERALD, a Phase 1/2 study of Treyegen (OKG-0303) for acute infectious conjunctivitis. Material Details #DetailAI Analyst View1CDSCO authorizes EMERALD trialRegulatory clearance enables human studies in India, a key step toward clinical validation and potential market access.2Phase 1/2 for OKG-0303Early clinical stage; outcome will set trajectory for further development and valuation.3Indication: acute…